The assessment of potential for QT interval prolongation with new pharmaceuticals: Impact on drug development
- 30 April 2000
- journal article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 43 (2) , 91-99
- https://doi.org/10.1016/s1056-8719(00)00100-3
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Long QT syndromes and torsade de pointesThe Lancet, 1999
- Acquired QT ProlongationCardiology in Review, 1998
- Systemic Antifungal AgentsDrug Safety, 1998
- Anticholinergic Overdose Induced Torsade de Pointes Successfully Treated with Verapamil.Japanese Heart Journal, 1996
- Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastineThe American Journal of Cardiology, 1994
- Torsade de PointesDrugs, 1994
- Torsade de pointes induced by astemizole in a patient with prolongation of the QT intervalAmerican Heart Journal, 1993
- An improved method to correct the QT interval of the electrocardiogram for changes in heart rateJournal of Pharmacological Methods, 1989
- Physiologic relation between cardiac cycle and QT duration in healthy volunteersThe American Journal of Cardiology, 1989
- Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarctionThe American Journal of Cardiology, 1982